吉西他滨化疗联合PD-1/PD-L1阻断治疗胰腺导管腺癌的研究进展

Research Progress on Gemcitabine Chemotherapy Combined with PD-1/PD-L1 Inhibitors for Pancreatic Ductal Adenocarcinoma

胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)不仅对于PD-1/PD-L1阻断剂单药治疗无效,而且对于常用的吉西他滨化疗也产生了耐药性,原因可能是PDAC具有独特的肿瘤微环境。目前,已有相关研究报道吉西他滨加抗PD-1抗体治疗延长了PDAC肝转移小鼠模型的生存期。全文综述PDAC对吉西他滨治疗产生耐药性的机制,并且探讨了抗PD-1/PD-L1抗体联合吉西他滨治疗PDAC可改善患者生存期的可能性。

Pancreatic ductal adenocarcinoma(PDAC)is usually resistant to PD-1/PD-L1 inhibitor monotherapy,as well as to gemcitabine chemotherapy,probably due to the unique tumor microenvironment of PDAC.Recent studies have shown that PD-1/PD-L1 inhibitors administrated with gemcitabine may prolong the survival of PDAC-bearing mice with liver metastasis,which brought new clue for clinical study.This paper reviews the mechanisms of PDAC resistant to PD-1/PD-L1 inhibitors and gemcitabine therapy,also explores the possibility of the combination of PD-1/PD-L1 inhibitors and gemcitabine for increasing treatment efficacy and improving survival of PDAC patients.